Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set

QTORIN™ rapamycin could become the first FDA-approved therapy for microcystic lymphatic malformations, a serious lifelong rare disease. The article estimates that more than 30,000 children and adults in the U.S. have been diagnosed; it does not report an FDA approval.